Table 1 Demographics and clinicopathologic characteristics of all patients
From: Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
Characteristics | Patients n (%) |
|---|---|
Median age, years (range) | 52 (28–76) |
Sex | |
Male | 21 (75.0) |
Female | 7 (25.0) |
Mean initial maximum diameter (range), cm | 10.7 (5.2–19.0) |
Primary location | |
Stomach | 8 (28.6) |
Small intestine | 9 (32.1) |
Colon | 2 (7.1) |
Rectum | 6 (21.4) |
Other | 3 (10.7) |
CD117 positivity | 26 (92.9) |
CD34 positivity | 21 (75.0) |
Median follow-up (range), months | 21 (8–75) |